139 related articles for article (PubMed ID: 8457659)
1. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review.
Nieuwenhuizen W
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):93-6. PubMed ID: 8457659
[TBL] [Abstract][Full Text] [Related]
2. [Molecular markers for the blood coagulation and fibrinolysis].
Okajima K
Rinsho Byori; 2001 Mar; Suppl 115():74-90. PubMed ID: 11391940
[TBL] [Abstract][Full Text] [Related]
3. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
Koga S
Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
[TBL] [Abstract][Full Text] [Related]
4. Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis.
Ieko M; Nakabayashi T; Tarumi T; Naito S; Yoshida M; Kanazawa K; Mizukami K; Koike T
Clin Chim Acta; 2007; 386(1-2):38-45. PubMed ID: 17803984
[TBL] [Abstract][Full Text] [Related]
5. Are fibrin-related markers useful for the diagnosis of thrombosis?
Wada H; Sakuragawa N
Semin Thromb Hemost; 2008 Feb; 34(1):33-8. PubMed ID: 18393141
[TBL] [Abstract][Full Text] [Related]
6. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
[TBL] [Abstract][Full Text] [Related]
7. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state.
Dempfle CE
Thromb Haemost; 1999 Aug; 82(2):673-83. PubMed ID: 10605767
[TBL] [Abstract][Full Text] [Related]
8. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers.
Omote M; Asakura H; Takamichi S; Shibayama M; Yoshida T; Kadohira Y; Maekawa M; Yamazaki M; Morishita E; Nakao S; Wada T
Thromb Res; 2008; 123(2):390-5. PubMed ID: 18579183
[TBL] [Abstract][Full Text] [Related]
9. [Soluble fibrin monomer complexes in thromboembolism].
Gryglik J
Przegl Lek; 1982 Sep; 39(8):551-3. PubMed ID: 6753042
[No Abstract] [Full Text] [Related]
10. A rapid monoclonal antibody-based enzyme immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma.
Nieuwenhuizen W; Hoegee-De Nobel E; Laterveer R
Thromb Haemost; 1992 Sep; 68(3):273-7. PubMed ID: 1440491
[TBL] [Abstract][Full Text] [Related]
11. [Study of hemostatic molecular marker].
Wada H; Ioka M
Rinsho Byori; 1997 Apr; 45(4):310-4. PubMed ID: 9136593
[TBL] [Abstract][Full Text] [Related]
12. Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women.
Peverill RE; Teede HJ; Malan E; Kotsopoulos D; Smolich JJ; McGrath BP
Clin Sci (Lond); 2007 Nov; 113(9):383-91. PubMed ID: 17608627
[TBL] [Abstract][Full Text] [Related]
13. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation.
Okajima K; Uchiba M; Murakami K; Okabe H; Takatsuki K
Am J Hematol; 1996 Mar; 51(3):186-91. PubMed ID: 8619398
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the pro-thrombotic state in CAPD patients.
Preloznik Zupan I; Sabovic M; Salobir B; Buturovic Ponikvar J
Ren Fail; 2008; 30(6):597-602. PubMed ID: 18661409
[TBL] [Abstract][Full Text] [Related]
15. [Soluble fibrin is not excreted in urine and its plasma level is elevated in nephrotic syndrome].
Morikawa T; Yamashiro Y; Okano K; Kasamatsu M; Sugai H; Kitamura H; Ohba I; Hotta O; Taguma Y; Sakurai J; Kitamoto Y
Rinsho Byori; 2009 Apr; 57(4):319-23. PubMed ID: 19489432
[TBL] [Abstract][Full Text] [Related]
16. A new enzyme immunoassay for soluble fibrin in plasma, with a high discriminating power for thrombotic disorders.
Bos R; Laterveer-Vreeswijk GH; Lockwood D; Szewczyk K; Nieuwenhuizen W
Thromb Haemost; 1999 Jan; 81(1):54-9. PubMed ID: 9974375
[TBL] [Abstract][Full Text] [Related]
17. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy.
McCarron BI; Marder VJ; Francis CW
Thromb Haemost; 1999 Dec; 82(6):1722-9. PubMed ID: 10613661
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of soluble fibrin in plasma by affinity chromatography--a comparative study with desAA-fibrin, desAABB-fibrin and fibrinogen.
Thiel W; Delvos U; Müller-Berghaus G
Thromb Haemost; 1985 Aug; 54(2):533-8. PubMed ID: 4082091
[TBL] [Abstract][Full Text] [Related]
19. [Simultaneous quantification of soluble fibrin and D-dimer in blood plasma for the assessment of the threat of thrombosis].
Lugovskii EV; Kolesnikova IN; Platonova TN; Lugovskaia NE; Litvinova LM; Kostiuchenko EP; Chernyshenko TM; Ganova LA; Spivak NIa; Komisarenko SV
Klin Med (Mosk); 2013; 91(11):38-44. PubMed ID: 25696964
[TBL] [Abstract][Full Text] [Related]
20. [Application of hemostatic molecular markers for diagnosis of thrombosis].
Wada H; Sakakura M; Nobori T; Shiku H
Rinsho Byori; 2000 Apr; 48(4):301-7. PubMed ID: 10810874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
